- Home
- LAB
as 11-15-2024 4:00pm EST
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 642.1M | IPO Year: | 2011 |
| Target Price: | $2.88 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.21 - $3.04 | Next Earning Date: | 10-30-2024 |
| Revenue: | $155,902,000 | Revenue Growth: | 48.23% |
| Revenue Growth (this year): | 62.6% | Revenue Growth (next year): | 9.91% |
Stock Insider Trading Activity of Standard BioTools Inc. (LAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | Aug 27 '24 | Buy | $2.19 | 250,000 | $546,750.00 | 54,025,821 | |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | Aug 22 '24 | Buy | $2.08 | 750,000 | $1,546,237.01 | 54,025,821 | |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | Aug 19 '24 | Buy | $1.88 | 1,250,000 | $2,351,875.00 | 54,025,821 |
Latest Standard BioTools Inc. News
LAB Breaking Stock News: Dive into LAB Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Standard BioTools Appoints Alex Kim as CFO
GlobeNewswire
10 days ago
Standard BioTools Appoints Alex Kim as Chief Financial Officer
Simply Wall St.
15 days ago
Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17
Simply Wall St.
16 days ago
Standard BioTools Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
17 days ago
Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ...
GlobeNewswire
17 days ago
Standard BioTools to Participate in Upcoming Investor Conferences
Zacks
18 days ago
Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
18 days ago
Standard BioTools: Q3 Earnings Snapshot
Compare LAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LAB Standard BioTools Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.